BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Seattle - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinseattle.com
X-WR-CALDESC:Events for Science in Seattle
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220120T103000
DTEND;TZID=America/Vancouver:20220120T113000
DTSTAMP:20260513T124051
CREATED:20220110T184250Z
LAST-MODIFIED:20220110T184250Z
UID:16225-1642674600-1642678200@scienceinseattle.com
SUMMARY:Distinguished Seminar Series - Nii Addy
DESCRIPTION:The Distinguished Seminar Series features presentations by outstanding thinkers and scientists\, sponsored by the Allen Institute for Brain Science. Distinguished speakers are selected based on the impact of their interdisciplinary research to the neuroscience community. Speakers spend a full day visiting with research staff\, are nominated by members of the Allen Institute\, and selected by a committee of peers. \nDr. Addy’s research focuses on the neurobiological processes underlying substance use disorders\, mood disorders\, and comorbid substance use and mood disorders. Dr. Addy’s team uses multiple methodologies\, including behavioral paradigms such as intravenous drug self-administration\, acute and chronic stress paradigms\, and anxiety and amotivation paradigms\, along with integrated pharmacological\, in vivo electrochemical\, and in vivo optogenetic methods to investigate these mechanisms. Dr. Addy will present his preclinical findings\, revealing cholinergic and L-type calcium channel processes in the mesolimbic dopamine reward system that robustly mediate substance use and mood disorder behavioral phenotypes through regulation of dopaminergic activity. Dr. Addy will also describe ongoing work with potential therapeutic compounds\, targeting subtype-specific muscarinic receptors and L-type calcium channels. Finally\, he will describe upcoming clinical collaborative studies\, based on his team’s recent preclinical findings.
URL:https://scienceinseattle.com/event/distinguished-seminar-series-nii-addy/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220120T103000
DTEND;TZID=America/Vancouver:20220120T113000
DTSTAMP:20260513T124051
CREATED:20220110T184250Z
LAST-MODIFIED:20220110T184250Z
UID:25833-1642674600-1642678200@scienceinseattle.com
SUMMARY:Distinguished Seminar Series - Nii Addy
DESCRIPTION:The Distinguished Seminar Series features presentations by outstanding thinkers and scientists\, sponsored by the Allen Institute for Brain Science. Distinguished speakers are selected based on the impact of their interdisciplinary research to the neuroscience community. Speakers spend a full day visiting with research staff\, are nominated by members of the Allen Institute\, and selected by a committee of peers. \nDr. Addy’s research focuses on the neurobiological processes underlying substance use disorders\, mood disorders\, and comorbid substance use and mood disorders. Dr. Addy’s team uses multiple methodologies\, including behavioral paradigms such as intravenous drug self-administration\, acute and chronic stress paradigms\, and anxiety and amotivation paradigms\, along with integrated pharmacological\, in vivo electrochemical\, and in vivo optogenetic methods to investigate these mechanisms. Dr. Addy will present his preclinical findings\, revealing cholinergic and L-type calcium channel processes in the mesolimbic dopamine reward system that robustly mediate substance use and mood disorder behavioral phenotypes through regulation of dopaminergic activity. Dr. Addy will also describe ongoing work with potential therapeutic compounds\, targeting subtype-specific muscarinic receptors and L-type calcium channels. Finally\, he will describe upcoming clinical collaborative studies\, based on his team’s recent preclinical findings.
URL:https://scienceinseattle.com/event/distinguished-seminar-series-nii-addy-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220120T103000
DTEND;TZID=America/Vancouver:20220120T113000
DTSTAMP:20260513T124051
CREATED:20220110T184250Z
LAST-MODIFIED:20220110T184250Z
UID:26798-1642674600-1642678200@scienceinseattle.com
SUMMARY:Distinguished Seminar Series - Nii Addy
DESCRIPTION:The Distinguished Seminar Series features presentations by outstanding thinkers and scientists\, sponsored by the Allen Institute for Brain Science. Distinguished speakers are selected based on the impact of their interdisciplinary research to the neuroscience community. Speakers spend a full day visiting with research staff\, are nominated by members of the Allen Institute\, and selected by a committee of peers. \nDr. Addy’s research focuses on the neurobiological processes underlying substance use disorders\, mood disorders\, and comorbid substance use and mood disorders. Dr. Addy’s team uses multiple methodologies\, including behavioral paradigms such as intravenous drug self-administration\, acute and chronic stress paradigms\, and anxiety and amotivation paradigms\, along with integrated pharmacological\, in vivo electrochemical\, and in vivo optogenetic methods to investigate these mechanisms. Dr. Addy will present his preclinical findings\, revealing cholinergic and L-type calcium channel processes in the mesolimbic dopamine reward system that robustly mediate substance use and mood disorder behavioral phenotypes through regulation of dopaminergic activity. Dr. Addy will also describe ongoing work with potential therapeutic compounds\, targeting subtype-specific muscarinic receptors and L-type calcium channels. Finally\, he will describe upcoming clinical collaborative studies\, based on his team’s recent preclinical findings.
URL:https://scienceinseattle.com/event/distinguished-seminar-series-nii-addy-3/
LOCATION:Online
END:VEVENT
END:VCALENDAR